CRGX — CARGO Therapeutics Share Price
0.000.00%
Last trade - 00:00- $198.95m
- -$140.76m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.55 | ||
| Price to Tang. Book | 0.55 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -48.16% | ||
| Return on Equity | -43.76% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CARGO Therapeutics, Inc. is a biotechnology company focused on the development of best-in-class and potentially curative cell therapies for cancer patients. It has a focused pipeline that includes its CRG-023 product candidate, a CD19/CD20/CD22 tri-specific CAR T developed using a tri-cistronic construct and designed to address several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy across a range of B-cell malignancies with the goal of providing more patients with a durable complete response. Its latest program advancement, an allogeneic platform, is a universal vector solution designed to limit immune-based rejection and enable durable response of CAR T-cell therapy. The universal allogeneic-enabling vector is intended to be paired with any CAR vector to create an allogeneic CAR T-cell therapy, with the potential to maintain the efficacy, durability, and safety of autologous cell therapy while broadening availability to more people with cancer.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 18th, 2019
- Public Since
- November 10th, 2023
- No. of Shareholders
- 22
- No. of Employees
- 167
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 46,052,368
- Address
- 835 Industrial Road, Suite 400, SAN CARLOS, 94070
- Web
- https://cargo-tx.com
- Phone
- +1 6504998950
- Auditors
- Deloitte & Touche LLP
Upcoming Events for CRGX
CARGO Therapeutics Inc Annual Shareholders Meeting
Q2 2025 CARGO Therapeutics Inc Earnings Release
Similar to CRGX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the CARGO Therapeutics share price?
As of Today at 19:48 UTC, shares in CARGO Therapeutics are trading at $4.32. This share price information is delayed by 15 minutes.
How has the CARGO Therapeutics share price performed this year?
Shares in CARGO Therapeutics last closed at $4.32 and the price had moved by -79.39% over the past 365 days. In terms of relative price strength the CARGO Therapeutics share price has underperformed the S&P500 Index by -81.41% over the past year.
What are the analyst and broker recommendations for CARGO Therapeutics?
The overall consensus recommendation for CARGO Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the CARGO Therapeutics dividend yield?
CARGO Therapeutics does not currently pay a dividend.
Does CARGO Therapeutics pay a dividend?
CARGO Therapeutics does not currently pay a dividend.
When does CARGO Therapeutics next pay dividends?
CARGO Therapeutics does not currently pay a dividend.
How do I buy CARGO Therapeutics shares?
To buy shares in CARGO Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CARGO Therapeutics?
As of the previous close price of $4.32, shares in CARGO Therapeutics had a market capitalisation of $198.95m.
Where are CARGO Therapeutics shares listed?
Here are the trading details for CARGO Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CRGX
What kind of share is CARGO Therapeutics?
Based on an overall assessment of its quality, value and momentum CARGO Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CARGO Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in CARGO Therapeutics is $10.68. That is 147.22% above the last closing price of $4.32.
Analysts covering CARGO Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.71 for the next financial year.
Find out moreWhat is the trend in the CARGO Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CARGO Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -78.7%.
As of the last closing price of $4.32, shares in CARGO Therapeutics were trading -67.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CARGO Therapeutics PE Ratio?
The CARGO Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CARGO Therapeutics?
We do not have data on CARGO Therapeutics' directors